A Clinical Trial of Fluvoxamine for Melancholia

• Status: Unknown status
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for endogenous depression. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lingjiang Li
• Treatments: Fluvoxamine

Criteria

Inclusion Criteria:

• Adult (18-55 years, both sexes), with DSM-4 criteria for MDD without psychosis, as determined by a structured clinical interview Mini International Neuropsychiatric Interview

• Moderate to severe depression, as defined by a pretreatment score ≥17 on the HDRS-17 scale

• Informed consent to participate in this study

• ethinic Han, right-handed, Junior high school education or above

Exclusion Criteria:

• A history of bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses; active suicidal intention, as determined by clinical interview

• Active or recent (<12 months) substance abuse or dependence; excluding nicotine

• Presence of ECT treatment in recent 6 months

• period of pregnancy or lactation

• hearing disorder or colour blindness

• Immediate relatives have bipolar disorder or mania disorder